These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 35276964)
1. Nutraceuticals for Dyslipidaemia and Glucometabolic Diseases: What the Guidelines Tell Us (and Do Not Tell, Yet). Casula M; Catapano AL; Magni P Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276964 [TBL] [Abstract][Full Text] [Related]
2. Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy. Colletti A; Fratter A; Pellizzato M; Cravotto G Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432457 [TBL] [Abstract][Full Text] [Related]
3. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. Penson PE; Banach M Nutrients; 2021 Aug; 13(9):. PubMed ID: 34578834 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Applications of Plant and Nutraceutical-Based Compounds for the Management of Type 2 Diabetes Mellitus: A Narrative Review. Dinesh S; Sharma S; Chourasiya R Curr Diabetes Rev; 2024; 20(2):e050523216593. PubMed ID: 37151065 [TBL] [Abstract][Full Text] [Related]
5. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings. Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510 [TBL] [Abstract][Full Text] [Related]
6. Management of metabolic syndrome and associated cardiovascular risk factors. De Flines J; Scheen AJ Acta Gastroenterol Belg; 2010; 73(2):261-6. PubMed ID: 20690566 [TBL] [Abstract][Full Text] [Related]
7. [Diabetic dyslipidaemia and the atherosclerosis]. Márk L; Dani G Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274 [TBL] [Abstract][Full Text] [Related]
8. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. Newcomer JW CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156 [TBL] [Abstract][Full Text] [Related]
9. Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies. Jain S; Buttar HS; Chintameneni M; Kaur G Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):145-157. PubMed ID: 30109827 [TBL] [Abstract][Full Text] [Related]
10. DIABRISK-SL prevention of cardio-metabolic disease with life style modification in young urban Sri Lankan's--study protocol for a randomized controlled trial. Wijesuriya M; Gulliford M; Vasantharajah L; Viberti G; Gnudi L; Karalliedde J Trials; 2011 Sep; 12():209. PubMed ID: 21943067 [TBL] [Abstract][Full Text] [Related]
11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620 [TBL] [Abstract][Full Text] [Related]
12. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Chapman MJ; Sposito AC Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759 [TBL] [Abstract][Full Text] [Related]
13. Nutraceutical regulations: An opportunity in ASEAN countries. Tripathi C; Girme A; Champaneri S; Patel RJ; Hingorani L Nutrition; 2020 Jun; 74():110729. PubMed ID: 32203878 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes. Watts GF; Chan DC Atheroscler Suppl; 2010 Jun; 11(1):61-4. PubMed ID: 20452838 [TBL] [Abstract][Full Text] [Related]
15. Nutraceuticals in Paediatric Patients with Dyslipidaemia. Banderali G; Capra ME; Viggiano C; Biasucci G; Pederiva C Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276928 [TBL] [Abstract][Full Text] [Related]
16. Management of Dyslipidemia in Individuals with Low-to-Moderate Cardiovascular Risk: Role of Nutraceuticals. Dolzhenko MM; Barnett OY; Grassos C; Dragomiretska NV; Goloborodko BI; Ilashchuk TO; Zuiev KO; Karpenko OV; Kolesnikova OV; Kolesnyk TV; Talaieva TV; Vakaliuk IP; Tiabut TD; Mesnikova IL; Zinych OV Adv Ther; 2020 Nov; 37(11):4549-4567. PubMed ID: 32979190 [TBL] [Abstract][Full Text] [Related]
17. [Low-grade systemic inflammation and the development of metabolic diseases: from the molecular evidence to the clinical practice]. León-Pedroza JI; González-Tapia LA; del Olmo-Gil E; Castellanos-Rodríguez D; Escobedo G; González-Chávez A Cir Cir; 2015; 83(6):543-51. PubMed ID: 26159364 [TBL] [Abstract][Full Text] [Related]
18. Pattern of dyslipidaemia and impact of increasing age and duration of type 2 diabetes mellitus on dyslipidaemia, insulin levels and insulin resistance. Nadeem A; Mumtaz S; Naveed AK; Aslam M; Siddiqui A; Lodhi GM J Pak Med Assoc; 2015 Sep; 65(9):928-32. PubMed ID: 26338734 [TBL] [Abstract][Full Text] [Related]
19. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Keating GM; Croom KF Drugs; 2007; 67(1):121-53. PubMed ID: 17209672 [TBL] [Abstract][Full Text] [Related]